Coronary Revascularization Outcomes Within Necessary Sex and Gender Aspects
Launched by FEDERAL STATE BUDGETARY INSTITUTION "FEDERAL CENTER FOR CARDIOVASCULAR SURGERY NAMED AFTER S.G. SUKH · Dec 23, 2024
Trial Information
Current as of June 28, 2025
Completed
Keywords
ClinConnect Summary
This retrospective-prospective single-centre study aims to conduct an in-depth comparative analysis of the impact of preoperative profile and range of surgical techniques in coronary artery bypass grafting (CABG) surgery on short-term and long-term outcomes in women and men.
The study included a sample of 400 patients (200 women and 200 men) who underwent CABG between January 2016 and July 2023. Patients enrolled in the study were divided into groups based on sex with the following propensity score matching (PSM) analysis, as well as into stratum of surgery techniques - ONCAB (on-pump coro...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients with multivessel coronary artery disease requiring CABG;
- • age ≥ 18 years;
- • patients residing in the Perm region.
- Exclusion Criteria:
- • single-vessel CABG;
- • redo CABG;
- • concomitant coronary artery disease and caroid artery disease and/or valvular disease and/or rhythm disorders requiring surgical treatment
About Federal State Budgetary Institution "Federal Center For Cardiovascular Surgery Named After S.G. Sukh
The Federal State Budgetary Institution "Federal Center for Cardiovascular Surgery Named After S.G. Suk" is a prominent clinical trial sponsor dedicated to advancing the field of cardiovascular medicine through innovative research and clinical excellence. Located in Russia, the Center specializes in the development and implementation of cutting-edge surgical techniques and therapies aimed at improving patient outcomes in cardiovascular health. With a strong focus on collaboration and scientific rigor, the institution actively participates in clinical trials that contribute to the global body of knowledge surrounding cardiovascular diseases, ultimately enhancing treatment options and care standards for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Perm, Perm Kray, Russian Federation
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported